KeifeRx CEO Chris Hoyt to Speak at the 2nd Annual Neuroscience Innovation Partnering & Licensing Summit in Boston
MCLEAN, VA, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- KeifeRx, a privately held biopharmaceutical company developing oral, brain-penetrant kinase inhibitors for neurodegenerative diseases, today announced that Chief Executive Officer Chris Hoyt …